NutraLife Biosciences Total Assets 2013-2022 | NLBS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NutraLife Biosciences total assets from 2013 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

NutraLife Biosciences total assets from 2013 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$232B
Amgen (AMGN)	$157.3B
Gilead Sciences (GILD)	$131.2B
Vertex Pharmaceuticals (VRTX)	$118.7B
Bristol Myers Squibb (BMY)	$110.5B
CSL (CSLLY)	$80B
GSK (GSK)	$75.9B
Regeneron Pharmaceuticals (REGN)	$74.3B
Argenex SE (ARGX)	$38.8B
Alnylam Pharmaceuticals (ALNY)	$32.4B
BioNTech SE (BNTX)	$29.4B
BeiGene (ONC)	$23.3B
Biogen (BIIB)	$20B
Illumina (ILMN)	$16B
Insmed (INSM)	$14.6B
Genmab (GMAB)	$14.4B
Genmab (GNMSF)	$14.3B
Incyte (INCY)	$13.8B
Moderna (MRNA)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.6B
BioMarin Pharmaceutical (BMRN)	$12.4B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Bio-Techne Corp (TECH)	$10.3B
Vaxcyte (PCVX)	$10.3B
Sarepta Therapeutics (SRPT)	$10.1B
Exelixis (EXEL)	$9.6B
Ascendis Pharma (ASND)	$9.5B
Exact Sciences (EXAS)	$9.2B
QIAGEN (QGEN)	$8.9B
Bio-Rad Laboratories (BIO.B)	$8.7B